“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

“Pseudoprogression” of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy

Published:2016-10 Issue:10 Volume:11 Page:e117-e119
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ito Kentaro,Hataji Osamu,Katsuta Koji,Kobayashi Tetsu,Gabazza Esteban C.,Yatabe Yasushi,Taguchi Osamu,Yamamoto Nobuyuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

2. Pseudoprogression and immune-related response in solid tumors;Chiou;J Clin Oncol,2015

3. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas;Kim;Eur J Cancer,2015

4. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer;Shukuya;J Thorac Oncol,2016

5. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer;Rizvi;Science,2015

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition;OncoImmunology;2024-02-07

2. Metastatic Pleomorphic Carcinoma of the Lung with Extensive Chromosomal Rearrangements: An Autopsy Case with a Literature Review;Internal Medicine;2024

3. Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy;Immunotherapy;2022-10

4. Pseudoprogression of lung large cell neuroendocrine carcinoma resembling pancreatic cancer during durvalumab therapy;Clinical Journal of Gastroenterology;2022-01-04

5. Pseudoprogression in lung cancer patients treated with immunotherapy;Critical Reviews in Oncology/Hematology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3